Literature DB >> 27330125

Design Considerations for Artificial Pancreas Pivotal Studies.

Steven J Russell1, Roy W Beck2.   

Abstract

The development of artificial pancreas systems has evolved to the point that pivotal studies designed to assess efficacy and safety are in progress or soon to be initiated. These pivotal studies are intended to provide the necessary data to gain clearance from the U.S. Food and Drug Administration, coverage by payers, and adoption by patients and clinicians. Although there will not be one design that is appropriate for every system, there are certain aspects of protocol design that will be considerations in all pivotal studies designed to assess efficacy and safety. One key aspect of study design is the intervention to be used by the control group. A case can be made that the control group should use the currently available best technology, which is sensor-augmented pump therapy. However, an equally, if not more, compelling case can be made that the control intervention should be usual care. In this Perspective, we elaborate on this issue and provide a pragmatic approach to the design of clinical trials of artificial pancreas systems.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Year:  2016        PMID: 27330125     DOI: 10.2337/dc15-2449

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system.

Authors:  Laya Ekhlaspour; Gregory P Forlenza; Daniel Chernavvsky; David M Maahs; R Paul Wadwa; Mark D Deboer; Laurel H Messer; Marissa Town; Jennifer Pinnata; Geoff Kruse; Boris P Kovatchev; Bruce A Buckingham; Marc D Breton
Journal:  Pediatr Diabetes       Date:  2019-05-23       Impact factor: 4.866

2.  Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.

Authors:  Firas H El-Khatib; Courtney Balliro; Mallory A Hillard; Kendra L Magyar; Laya Ekhlaspour; Manasi Sinha; Debbie Mondesir; Aryan Esmaeili; Celia Hartigan; Michael J Thompson; Samir Malkani; J Paul Lock; David M Harlan; Paula Clinton; Eliana Frank; Darrell M Wilson; Daniel DeSalvo; Lisa Norlander; Trang Ly; Bruce A Buckingham; Jamie Diner; Milana Dezube; Laura A Young; April Goley; M Sue Kirkman; John B Buse; Hui Zheng; Rajendranath R Selagamsetty; Edward R Damiano; Steven J Russell
Journal:  Lancet       Date:  2016-12-20       Impact factor: 79.321

3.  Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections.

Authors:  Tonya Riddlesworth; David Price; Nathan Cohen; Roy W Beck
Journal:  Diabetes Ther       Date:  2017-06-14       Impact factor: 2.945

4.  Assessing patient-reported outcomes for automated insulin delivery systems: the psychometric properties of the INSPIRE measures.

Authors:  J Weissberg-Benchell; J B Shapiro; K Hood; L M Laffel; D Naranjo; K Miller; K Barnard
Journal:  Diabet Med       Date:  2019-03-20       Impact factor: 4.359

5.  The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes.

Authors:  Boris Kovatchev; William V Tamborlane; William T Cefalu; Claudio Cobelli
Journal:  Diabetes Care       Date:  2016-07       Impact factor: 19.112

6.  Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.

Authors:  Lia Bally; Hood Thabit; Harald Kojzar; Julia K Mader; Jehona Qerimi-Hyseni; Sara Hartnell; Martin Tauschmann; Janet M Allen; Malgorzata E Wilinska; Thomas R Pieber; Mark L Evans; Roman Hovorka
Journal:  Lancet Diabetes Endocrinol       Date:  2017-01-14       Impact factor: 44.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.